Preclinical Phase

Wave Life Sciences Ltd (NASDAQ: WVE) presented new preclinical data for its ADAR-mediated RNA editing capability (ADAR editing) and an update on its discovery-stage alpha-1 antitrypsin deficiency (AATD) program.  Related Link: Wave Life Sciences' RNA Editing Platform...

AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-...

Point Biopharma Global Inc (NASDAQ: PNT) has additional preclinical data from its fibroblast activation protein-alpha (FAP-alpha) inhibitor program, PNT2004.  The new data demonstrate rapid and persistent tumor targeting with very low retention in normal tissues. ...

Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce viral markers, including hepatitis B surface antigen (HBsAg) expression, and prevent viral rebound of hepatitis B virus (HBV...

Stealth BioTherapeutics Corp (NASDAQ: MITO) has presented new data from a study evaluating SBT-272 in a murine model of Parkinson's disease (PD).  SBT-272 is a mitochondria-targeted product candidate, which is known to cross the blood-brain barrier.  The data were...

TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.  Related: TransCode Therapeutics Secures NIH Funding To Support Its Lead Program Development. The preclinical...

Verve Therapeutics Inc (NASDAQ: VERV) has reported new preclinical data from 36 non-human primates (NHPs) with its lead candidate, VERVE-101. VERVE-101 is a potential single-course gene-editing treatment for atherosclerotic cardiovascular disease (ASCVD).  The data will be...

Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing.  The Company says that continued optimization of LNPs has led to a substantial increase in liver editing potency, which...

The Charcot–Marie–Tooth Association (CMTA), a philanthropic funder of CMT research worldwide, and Addex Therapeutics Ltd (NASDAQ: ADXN) have collaborated to investigate a potential therapy for CMT type 1A (CMT1A). Charcot-Marie-Tooth disease type 1A (CMT1A) is an...

Viridian Therapeutics Inc (NASDAQ: VRDN) has priced an underwritten public offering with approximately $85.0 million gross proceeds.  Viridian will offer 6.18 million shares at $11.00 per share, and 23,126 shares of series B preferred stock at a public offering price of $733.37 per...

Novartis AG (NYSE: NVS) has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio.  Deal terms were not disclosed. Related: Why Did Deutsche Bank Downgrade This Big...

NanoViricides Inc (NYSE: NNVC) has reported significant advantages gained by remdesivir encapsulation within its lead COVID-19 candidate, thus showing a potential pan-coronavirus cure. Related Link: EXCLUSIVE: NanoViricides Beefs Up Its COVID-19 Pipeline With TheraCour Licensing Pact....

PharmaCyte Biotech Inc (NASDAQ: PMCB) stock is moving higher in reaction to the first test results of the biocompatibility studies of its CypCaps trial product candidate. These results were from an "In Vitro Complement Activation Study of Empty Cellulose Sulphate Capsules," the same...

Phio Pharmaceuticals Corp (NASDAQ: PHIO) has announced preclinical results from a new study of a self-delivering RNAi (INTASYL) therapeutic platform. The data were presented at the European Society of Medical Oncology (ESMO) Congress 2021. The study was performed to show the...

The United States Patent and Trademark Office has issued a notice of patent allowance to Indaptus Therapeutics Inc's (NASDAQ: INDP) platform technology. The patent provides broad protection for applying the Company's platform technology alone and in combination with...